Company Focus
Novartis
Latest Novartis News
Pharmaceutical
Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered into a research collaboration and license agreement with Novartis. 13 November 2024
Related News
Insights
Company Spotlight
A biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
Latest News & Features of interest to Novartis
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
Norwegian clinical-stage biotech Nykode Therapeutics revealed that it has received notification from Genentech, a US subsidiary of Roche, of its decision to terminate the collaboration and licensing agreement for Nykode’s VB10.NEO cancer vaccine program. 12 November 2024
Pharmaceutical
Merck KGaA today announced that the Phase III MANEUVER trial of pimicotinib met its primary endpoint, demonstrating significant improvement in objective response rate (ORR) in patients with tenosynovial giant cell tumor (TGCT). The ORR for pimicotinib at week 25 was 54.0% compared with 3.2% for placebo (p<0.0001). 12 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Pharmaceutical
Germany’s Bayer saw its shares tumble almost 11% to 21.76 euros this morning, as it reported level third-quarter 2024 sales while earnings declined. 12 November 2024
Biotechnology
23andMe, a human genetics firm and consumer health innovator, has announced a major restructuring, cutting approximately 40% of its workforce. 12 November 2024
Pharmaceutical
US drugmaker AbbVie was trading more than 11% lower early on Monday afternoon in New York. 11 November 2024
Biotechnology
The combination of Merck & Co’s Keytruda (pembrolizumab) and Citius Pharmaceuticals’ Lymphir (denileukin diftitox-cxdl) showed promising preliminary results in an investigator-initiated Phase I clinical trial for cancer patients with recurrent solid tumors. 11 November 2024
article
US company IDEAYA Biosciences has exercised the option for an exclusive worldwide license for Biocytogen Pharmaceuticals’ B7H3/PTK7 BsADC program, IDE034, and has nominated it as a development candidate. 11 November 2024
Biotechnology
On November 8, the US Food and Drug Administration approved Aucatzyl (obecabtagene autoleucel; obe-cel) from US biopharma Autolus Therapeutics' 11 November 2024
Latest In Brief for Novartis
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Latest Ones To Watch News
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
12 November 2024
5 November 2024
28 October 2024
Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze